Advertisement

Polypharmacy

  • Nicola FerraraEmail author
  • Graziamaria Corbi
  • Klara Komici
  • Giuseppe Rengo
Chapter

Abstract

Polypharmacy has been defined by the World Health Organization as “the administration of many drugs at the same time or the administration of an excessive number of drugs” [1]. Even if the use of more drugs in many cases has been justified by concomitant diseases and complex medical situations, it is not rare, especially in old patients, the prescription of more inappropriate drugs increasing the risk of iatrogenesis defined as adverse health effects caused by medical practices or drugs prescribed by doctors for the health of the patients at the usual way or doses.

Keywords

Inappropriate Prescription Inappropriate Drug Relevant Drug Interaction High Symptom Score Pulmonary Adverse Event 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Bibilography

  1. 1.
    WHO. Center for Health Development. A glossary of terms for community health care and services for older persons. In: Aging and health technical Report n. 5, 2004.Google Scholar
  2. 2.
    Ward BW, Schiller JS, Goodman RA. Multiple chronic conditions among US adults: a 2012 update. Prev Chronic Dis. 2014;11:E62.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Ferrara N, Terrosu P, Zuccalà G, Corsini A. Politerapia e polifarmacia nell’anziano con scompenso cardiaco cronico. G Ital Cardiol. 2013;14(3 Suppl 1):46S–51.Google Scholar
  4. 4.
    Cacciatore F, Abete P, Ferrara N, et al. Congestive heart failure and cognitive impairment in an older population. J Am Geriatr Soc. 1998;46(11):1343–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Cacciatore F, Gallo C, Ferrara N, et al. Morbidity patterns in aged population in southern Italy. A survey sampling. Arch Gerontol Geriatr. 1998;26(3):201–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Covinsky KE, Palmer RM, Fortinsky RH, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Ger Soc. 2003;51:451–8.CrossRefGoogle Scholar
  7. 7.
    Volpato S, Onder G, Cavalieri M, Guerra G, Sioulis F, Maraldi C, Zuliani G, Fellin R, Italian Group of Pharmacoepidemiology in the Elderly Study (GIFA). Characteristics of nondisabled older patients developing new disability associated with medical illnesses and hospitalization. J Gen Intern Med. 2007;22(5):668–74. Epub 2007 Mar 1.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rengo F, Acanfora D, Trojano L, et al. Congestive heart failure in the elderly. Arch Gerontol Geriatr. 1996;23(3):201–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Rich MW. Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Cardiol. 2005;14(3):134–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Testa G, Cacciatore F, Galizia G, et al. Depressive symptoms predict mortality in elderly subjects with chronic heart failure. Eur J Clin Invest. 2011;41(12):1310–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Testa G, Cacciatore F, Galizia G, et al. Charlson Comorbidity Index does not predict long-term mortality in elderly subjects with chronic heart failure. Age Ageing. 2009;38(6):734–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51.CrossRefPubMedGoogle Scholar
  13. 13.
    Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277(4):307–11.CrossRefPubMedGoogle Scholar
  14. 14.
    Corbi G, Acanfora D, Iannuzzi GL, et al. Hypermagnesemia predicts mortality in elderly with congestive heart disease: relationship with laxative and antacid use. Rejuvenation Res. 2008;11(1):129–38.CrossRefPubMedGoogle Scholar
  15. 15.
    Ferrara N, Abete P, Giordano M, et al. Neurotoxicity induced by cefepime in a very old hemodialysis patient. Clin Nephrol. 2003;59(5):388–90.CrossRefPubMedGoogle Scholar
  16. 16.
    Ferrara N, Corbi G, Capuano A, et al. Memantine-induced hepatitis with cholestasis in a very elderly patient. Ann Intern Med. 2008;148(8):631–2.CrossRefPubMedGoogle Scholar
  17. 17.
    Campobasso CP, Procacci R, Caligara M. Fatal adverse reaction to ketorolac tromethamine in asthmatic patient. Am J Forensic Med Pathol. 2008;29(4):358–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Larrey D. Hepatotoxicity of herbal remedies. J Hepatol. 1997;52:97–103.Google Scholar
  19. 19.
    Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297–303.CrossRefPubMedGoogle Scholar
  20. 20.
    Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc. 2002;50(7):1297–300.CrossRefPubMedGoogle Scholar
  21. 21.
    Marik PE, Fromm L. A case series of hospitalized patients with elevated digoxin levels. Am J Med. 1998;105(2):110–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Düngen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13(6):670–80.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther. 2003;17(3):265–85.CrossRefPubMedGoogle Scholar
  24. 24.
    Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? Curr Med Res Opin. 2011;27(8):1551–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Ferrara N, Davia K, Abete P, et al. Alterations in beta-adrenoceptor mechanisms in the aging heart: relationship with heart failure. Aging Clin Exp Res. 1997;9(6):391–403.CrossRefGoogle Scholar
  26. 26.
    Lindley CM, Tully MP, Paramsothy V, et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing. 1992;21:294–300.CrossRefPubMedGoogle Scholar
  27. 27.
    Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12.CrossRefPubMedGoogle Scholar
  28. 28.
    General Accounting Office (U.S.). Adverse drug events. GAO/HEHS-00-21; Jan 2000.Google Scholar
  29. 29.
    Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. Arch Intern Med. 1999;159(21):2553–60.CrossRefPubMedGoogle Scholar
  30. 30.
    Bates DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med. 1995;10(4):199–205.CrossRefPubMedGoogle Scholar
  31. 31.
    Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA. 1995;274(1):35–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Pimlott NJ, Hux JE, Wilson LM, et al. Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. CMAJ. 2003;168(7):835–9.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Gill SS. Bleeding complications in elderly patients following acute myocardial infarction. Arch Intern Med. 2005;165(20):2430–1.PubMedGoogle Scholar
  34. 34.
    Gambassi G, Lapane K, Sgadari A, et al. Prevalence, clinical correlates, and treatment of hypertension in elderly nursing home residents. SAGE (Systematic Assessment of Geriatric Drug Use via Epidemiology) Study Group. Arch Intern Med. 1998;158(21):2377–85.CrossRefPubMedGoogle Scholar
  35. 35.
    Passaro A, Volpato S, Romagnoni F, et al. Benzodiazepines with different half-life and falling in a hospitalized population: the GIFA study. Gruppo Italiano di Farmacovigilanza nell’Anziano. J Clin Epidemiol. 2000;53(12):1222–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc. 1991;39(11):1093–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Gray SL, Sager M, Lestico MR, et al. Adverse drug events in hospitalized elderly. J Gerontol A Biol Sci Med Sci. 1998;53(1):M59–63.CrossRefPubMedGoogle Scholar
  38. 38.
    Krousel-Wood M, Joyce C, Holt E, et al. Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension. 2011;58(5):804–10.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Rinaldi B, Corbi G, Boccuti S, et al. Exercise training affects age-induced changes in SOD and heat shock protein expression in rat heart. Exp Gerontol. 2006;41(8):764–70.CrossRefPubMedGoogle Scholar
  40. 40.
    Ferrara N, Rinaldi B, Corbi G, et al. Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res. 2008;11(1):139–50.CrossRefPubMedGoogle Scholar
  41. 41.
    Rengo G, Leosco D, Zincarelli C, et al. Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am J Physiol Heart Circ Physiol. 2010;298(6):H2032–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Corbi G, Conti V, Russomanno G, et al. Is physical activity able to modify oxidative damage in cardiovascular aging? Oxid Med Cell Longev. 2012;2012:728547. doi: 10.1155/2012/728547.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Conti V, Corbi G, Russomanno G, et al. Oxidative stress effects on endothelial cells treated with different athletes’ sera. Med Sci Sports Exerc. 2012;44(1):39–49.CrossRefPubMedGoogle Scholar
  44. 44.
    Ferrara N, Corbi G, Bosimini E, et al. Cardiac rehabilitation in the elderly: patient selection and outcomes. Am J Geriatr Cardiol. 2006;15(1):22–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Corbi G, Conti V, Scapagnini G, et al. Role of sirtuins, calorie restriction and physical activity in aging. Front Biosci (Elite Ed). 2012;4:768–78.Google Scholar
  46. 46.
    De Maeyer C, Beckers P, Vrints CJ, Conraads VM. Exercise training in chronic heart failure. Ther Adv Chronic Dis. 2013;4(3):105–17; Khazaeinia T, Ramsey AA, Tam YK. The effects of exercise on the pharmacokinetics of drugs. J Pharm Pharm Sci. 2000;3(3):292–302.Google Scholar
  47. 47.
    Gerety MB, Cornell JE, Plichta DT, et al. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc. 1993;41(12):1326–32.CrossRefPubMedGoogle Scholar
  48. 48.
    Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151:1825–32.CrossRefPubMedGoogle Scholar
  49. 49.
    Ryan C, O’Mahony D, Kennedy J, Weedle P, Cottrell E, Heffernan M, O’Mahony B, Byrne S. Potentially inappropriate prescribing in older residents in Irish nursing homes. Age Ageing. 2013;42(1):116–20.CrossRefPubMedGoogle Scholar
  50. 50.
    Corbi G, Gambassi G, Pagano G, et al. Impact of an innovative educational strategy on medication appropriate use and length of stay in elderly patients. Medicine (Baltimore). 2015;94(24):e918. doi: 10.1097/MD.0000000000000918.CrossRefGoogle Scholar
  51. 51.
    Chia LR, Schlenk EA, Dunbar-Jacob J. Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging. 2006;23(3):191–202.CrossRefPubMedGoogle Scholar
  52. 52.
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med. 2000;160(14):2101–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Gallant MP. The influence of social support on chronic illness self-management: a review and directions for research. Health Educ Behav. 2003;30(2):170–95.CrossRefPubMedGoogle Scholar
  54. 54.
    Haynes RB, Yao X, Degani A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2005;4. Art No:CD000011.Google Scholar
  55. 55.
    Haynes RB, McDonald H, Garg A, et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2. Art No: CD000011.Google Scholar
  56. 56.
    Sabaté E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. p. 1–209.Google Scholar
  57. 57.
    Schedlbauer A, Schroeder K, Peters TJ, et al. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2004;4. Art No:CD004371.Google Scholar
  58. 58.
    Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;3. Art No:CD004804.Google Scholar
  59. 59.
    Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–84.CrossRefPubMedGoogle Scholar
  60. 60.
    Williams A, Manias E, Walker R. Interventions to improve medication adherence in people with multiple chronic conditions: a systematic review. J Adv Nurs. 2008;63(2):132–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Nicola Ferrara
    • 1
    • 2
    Email author
  • Graziamaria Corbi
    • 3
  • Klara Komici
    • 1
  • Giuseppe Rengo
    • 1
    • 2
  1. 1.Department of Translational Medical SciencesUniversity of Naples “Federico II”NapoliItaly
  2. 2.S. Maugeri FoundationScientific Institute of Telese Terme (BN), IRCCSTelese TermeItaly
  3. 3.Department of Medicine and Health SciencesUniversity of MoliseCampobassoItaly

Personalised recommendations